Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient quality of life.
Oncopeptides uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
The headquarters is in Stockholm, Sweden, and a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.
2000
Served areaWorldwide
HeadquartersLuntmakargatan 46, 7th floor, 11137 Stockholm – Sweden
94,309,267
IPOFeb. 22, 2017
Stock exchange(s)Nasdaq Stockholm